smcc-dm-1

SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.

(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemic form of Lys-SMCC-DM1, which serves as a linker-payload component capable of inhibiting tubulin polymerization. It is also recognized as the active metabolite of T-DM1 [1].

Laprituximab emtansine (IMGN-289), an immunotoxin targeting HER1, is an EGFR antibody-drug conjugate (ADC) composed of J2898A antibody, DM1 (anti-microtubule agent), and the SMCC thioether linker, utilized in cancer research [1] [2] [3].

Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked with the SMCC linker and the cytotoxic microtubule inhibitor DM1. The ADC's toxic and linker components are SMCC-DM1. Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used for cancer research.

Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab linked to the cytotoxic microtubule inhibitor DM1 through the linker SMCC. The ADC's toxic molecule and linker component are SMCC-DM1. This compound is applicable in cancer research, particularly for studying prostate cancer.